UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

May 18, 2023

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

May 11, 2023

Shared insight on clinical trial data behind the intensification of maintenance immunotherapy in patients with metastatic urothelial carcinoma.

May 11, 2023

Centering discussion on several key clinical trials, expert panelists reflect on data behind maintenance avelumab in metastatic urothelial carcinoma.

May 04, 2023

A panel of four key opinion leaders discuss the role of maintenance therapy in metastatic urothelial carcinoma and how its use has impacted the treatment landscape.

May 04, 2023

A brief review of the appropriate number of chemotherapy cycles to utilize in the setting of metastatic urothelial carcinoma.

April 27, 2023

Switching their focus to the metastatic urothelial carcinoma treatment landscape, panelists identify cornerstone frontline treatment options.

April 27, 2023

A comprehensive review of novel treatment strategies in MIBC, including perioperative therapy, and respective ongoing clinical trials.

April 20, 2023

Expert panelists reflect on the molecular subtyping of patients to predict response to neoadjuvant therapy in Bladder BRIDGister.

April 20, 2023

Shared insight on the combination of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer in the HCRN GU 16-257 trial.

April 19, 2023

April is Head and Neck Cancer Awareness Month, and a promising new research initiative at UC Davis Comprehensive Cancer Center could lead to a new and far more effective standard of care for this group of cancers.

April 13, 2023

R. Lor Randall, MD, FACS, discusses the investigation of ganitumab plus standard-of-care interval-compressed chemotherapy in a phase 3 trial for newly diagnosed metastatic Ewing sarcoma.

April 13, 2023

Focused discussion on the RETAIN BLADDER study, which explored the option to avoid cystectomy in patients with good response to systemic therapy.

April 13, 2023

Continuing their discussion on adjuvant therapy in in muscle-invasive bladder cancer, panelists identify the utility of minimal residual disease testing.

April 11, 2023

R. Lor Randall, MD, FACS, expands on data from a phase 3 trial evaluating the addition of ganitumab to standard-of-care, interval-compressed chemotherapy, the implications of these results, and how the study could help inform future trials exploring other targeted therapies for the treatment of patients with metastatic Ewing sarcoma.

April 06, 2023

Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.

April 06, 2023

Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.

March 30, 2023

Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.

March 30, 2023

A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.

March 24, 2023

R. Lor Randall, MD, FACS, discusses the potential symptoms and presentation of mesenchymal chondrosarcoma, as well as highlighted recent case studies that he consulted on for patients with mesenchymal chondrosarcoma.

March 23, 2023

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.